DNA Sequencing-Based Monitoring of Minimal Residual Disease to Predict Clinical Relapse in Aggressive B-cell Non-Hodgkin Lymphomas
Typically, after completing initial treatment for diffuse large B-cell lymphoma (DLBCL), doctors monitor patients using computed tomography (CT scans) and a physical exam. Physicians want to find better ways of detecting lymphoma relapse and that is the purpose of this study.
Researchers in this study are evaluating a new technique called minimal residual disease (MRD) assessment. With this technique, they use very sensitive genetic technologies to see if they can find very small amounts of lymphoma cells circulating in a patient's bloodstream. This technology is designed to detect one lymphoma cell among one million white blood cells. The MRD assessment is a simple blood test.
The investigators want to see if MRD assessment is more, less, or equally as accurate as CT scans for detecting lymphoma relapse. They also want to determine if MRD assessment can identify lymphoma relapse sooner than CT scanning and a physical exam. Participants in this study will have blood tests every three months and CT scans every six months for up to two years after they finish treatment.
View a video explaining the basic principles and goals of the study for all participants.
To be eligible for this study, patients must meet several criteria, including but not limited to the following:
- Patients must be planning to receive, currently receiving, or recently completed the first regimen of chemotherapy for DLBCL.
- This study is for patients age 18 and older.
For more information and to inquire about eligibility for this study, please contact Dr. Anita Kumar at 212-639-2668.